These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
515 related articles for article (PubMed ID: 21059805)
21. Combretastatin A4-induced differential cytotoxicity and reduced metastatic ability by inhibition of AKT function in human gastric cancer cells. Lin HL; Chiou SH; Wu CW; Lin WB; Chen LH; Yang YP; Tsai ML; Uen YH; Liou JP; Chi CW J Pharmacol Exp Ther; 2007 Oct; 323(1):365-73. PubMed ID: 17646428 [TBL] [Abstract][Full Text] [Related]
22. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272 [TBL] [Abstract][Full Text] [Related]
23. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase. Igawa T; Lin FF; Rao P; Lin MF Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404 [TBL] [Abstract][Full Text] [Related]
24. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Ogunwobi OO; Beales IL Am J Gastroenterol; 2008 Apr; 103(4):825-37. PubMed ID: 18371146 [TBL] [Abstract][Full Text] [Related]
25. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. Maffucci T; Piccolo E; Cumashi A; Iezzi M; Riley AM; Saiardi A; Godage HY; Rossi C; Broggini M; Iacobelli S; Potter BV; Innocenti P; Falasca M Cancer Res; 2005 Sep; 65(18):8339-49. PubMed ID: 16166311 [TBL] [Abstract][Full Text] [Related]
26. Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells. Yang L; Egger M; Plattner R; Klocker H; Eder IE Urology; 2011 Jun; 77(6):1508.e1-7. PubMed ID: 21624609 [TBL] [Abstract][Full Text] [Related]
27. Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer. Bhattacharyya RS; Husbeck B; Feldman D; Knox SJ Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):935-40. PubMed ID: 18760546 [TBL] [Abstract][Full Text] [Related]
28. Preclinical antitumor activity of the oral platinum analog satraplatin. Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592 [TBL] [Abstract][Full Text] [Related]
29. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model. McGregor N; Patel L; Craig M; Weidner S; Wang S; Pienta KJ J Cell Biochem; 2010 Aug; 110(5):1187-94. PubMed ID: 20589722 [TBL] [Abstract][Full Text] [Related]
30. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth. Chen J; Ouyang ZG; Zhang SH; Zhen YS Oncol Rep; 2007 Jun; 17(6):1445-51. PubMed ID: 17487403 [TBL] [Abstract][Full Text] [Related]
32. Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis. Yasukochi A; Kawakubo T; Nakamura S; Yamamoto K Biol Chem; 2010 Aug; 391(8):947-58. PubMed ID: 20482316 [TBL] [Abstract][Full Text] [Related]
33. Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells. Lim JT; Piazza GA; Pamukcu R; Thompson WJ; Weinstein IB Clin Cancer Res; 2003 Oct; 9(13):4972-82. PubMed ID: 14581372 [TBL] [Abstract][Full Text] [Related]
35. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate cancer cells to TRAIL-induced apoptosis. Peuhu E; Rivero-Müller A; Stykki H; Torvaldson E; Holmbom T; Eklund P; Unkila M; Sjöholm R; Eriksson JE Oncogene; 2010 Feb; 29(6):898-908. PubMed ID: 19935713 [TBL] [Abstract][Full Text] [Related]
37. The therapeutic and preventive effect of RRR-alpha-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3. Yin Y; Ni J; Chen M; DiMaggio MA; Guo Y; Yeh S Clin Cancer Res; 2007 Apr; 13(7):2271-80. PubMed ID: 17404112 [TBL] [Abstract][Full Text] [Related]
38. Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer. Sankpal UT; Abdelrahim M; Connelly SF; Lee CM; Madero-Visbal R; Colon J; Smith J; Safe S; Maliakal P; Basha R Prostate; 2012 Nov; 72(15):1648-58. PubMed ID: 22473873 [TBL] [Abstract][Full Text] [Related]
39. PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer. Goc A; Al-Husein B; Kochuparambil ST; Liu J; Heston WW; Somanath PR Int J Oncol; 2011 Jan; 38(1):267-77. PubMed ID: 21109949 [TBL] [Abstract][Full Text] [Related]
40. Pancratistatin induces apoptosis and autophagy in metastatic prostate cancer cells. Griffin C; McNulty J; Pandey S Int J Oncol; 2011 Jun; 38(6):1549-56. PubMed ID: 21424119 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]